Is Human-induced Pluripotent Stem Cell the Best Optimal?
- Author:
Feng WANG
1
,
2
;
Jie KONG
3
;
Yi-Yao CUI
3
;
Peng LIU
1
;
Jian-Yan WEN
1
;
Author Information
- Publication Type:Journal Article
- Keywords: Cardiovascular Diseases; Embryonic Stem Cells; Induced Pluripotent Stem Cells
- MeSH: Cardiovascular Diseases; therapy; Embryonic Stem Cells; physiology; Humans; Induced Pluripotent Stem Cells; physiology; Regenerative Medicine; methods
- From: Chinese Medical Journal 2018;131(7):852-856
- CountryChina
- Language:English
-
Abstract:
ObjectiveSince the advent of induced pluripotent stem cell (iPSC) technology a decade ago, enormous progress has been made in stem cell biology and regenerative medicine. Human iPSCs have been widely used for disease modeling, drug discovery, and cell therapy development. In this review, we discuss the progress in applications of iPSC technology that are particularly relevant to drug discovery and regenerative medicine, and consider the remaining challenges and the emerging opportunities in the field.
Data SourcesArticles in this review were searched from PubMed database from January 2014 to December 2017.
Study SelectionOriginal articles about iPSCs and cardiovascular diseases were included and analyzed.
ResultsiPSC holds great promises for human disease modeling, drug discovery, and stem cell-based therapy, and this potential is only beginning to be realized. However, several important issues remain to be addressed.
ConclusionsThe recent availability of human cardiomyocytes derived from iPSCs opens new opportunities to build in vitro models of cardiac disease, screening for new drugs and patient-specific cardiac therapy.
